156 related articles for article (PubMed ID: 29175747)
1. Development and validation of a new HPLC-MS method for meglumine impurity profiling.
Martano C; Ferretti F; Ghiani S; Buonsanti F; Bruno E; Lattuada L; Medana C
J Pharm Biomed Anal; 2018 Feb; 149():517-524. PubMed ID: 29175747
[TBL] [Abstract][Full Text] [Related]
2. Determination of meglumine in pharmaceutical formulations using high performance liquid chromatography.
Jasprica I; Mrsić N; Dragić T; Cetina-Cizmek B
Pharmazie; 2011 Dec; 66(12):916-9. PubMed ID: 22312693
[TBL] [Abstract][Full Text] [Related]
3. Forced degradation and impurity profiling: recent trends in analytical perspectives.
Jain D; Basniwal PK
J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
[TBL] [Abstract][Full Text] [Related]
4. Elemental Impurities in Pharmaceutical Excipients.
Li G; Schoneker D; Ulman KL; Sturm JJ; Thackery LM; Kauffman JF
J Pharm Sci; 2015 Dec; 104(12):4197-4206. PubMed ID: 26398581
[TBL] [Abstract][Full Text] [Related]
5. Generation of formaldehyde by pharmaceutical excipients and its absorption by meglumine.
Fujita M; Ueda T; Handa T
Chem Pharm Bull (Tokyo); 2009 Oct; 57(10):1096-9. PubMed ID: 19801864
[TBL] [Abstract][Full Text] [Related]
6. A drug-excipient interaction impurity of bromhexine hydrochloride injection: Structure and formation mechanism elucidation.
Zhou M; Wu W; Pu H; Chen F; Yi C; Long Y
J Pharm Biomed Anal; 2024 Sep; 247():116256. PubMed ID: 38850847
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of meglumine in pharmaceutical products by means of high pressure liquid chromatography].
La Rotonda MI; Schettino O
Boll Soc Ital Biol Sper; 1978 Dec; 54(24):2590-4. PubMed ID: 756281
[TBL] [Abstract][Full Text] [Related]
8. Drug-excipient compatibility testing-Identification and characterization of degradation products of phenylephrine in several pharmaceutical formulations against the common cold.
Douša M; Gibala P; Havlíček J; Plaček L; Tkadlecová M; Břicháč J
J Pharm Biomed Anal; 2011 Jul; 55(5):949-56. PubMed ID: 21481557
[TBL] [Abstract][Full Text] [Related]
9. LC-MS characterization of trace impurities contained in calcium folinate.
Francese G; Corana F; Meneghetti O; Marazza F
J Pharm Biomed Anal; 2005 Sep; 39(3-4):757-63. PubMed ID: 15927438
[TBL] [Abstract][Full Text] [Related]
10. Study on the impurity profile and influencing factors of photodegradation in non-aqueous ofloxacin ear drops using liquid chromatography combined with ion trap/time-of-flight mass spectrometry.
Xu B; Gao J; Zhu B; Li P; Su W; Wang J
J Pharm Biomed Anal; 2023 Sep; 233():115476. PubMed ID: 37245330
[TBL] [Abstract][Full Text] [Related]
11. Comparison of impurity profiles of Orlistat pharmaceutical products using HPLC tandem mass spectrometry.
Schneider A; Wessjohann LA
J Pharm Biomed Anal; 2010 Nov; 53(3):767-72. PubMed ID: 20570457
[TBL] [Abstract][Full Text] [Related]
12. Identification of an Adduct Impurity of an Active Pharmaceutical Ingredient and a Leachable in an Ophthalmic Drug Product Using LC-QTOF.
Gollapalli R; Singh G; Blinder A; Brittin J; Sengupta A; Mondal B; Patel M; Pati B; Lee J; Ghode A; Kote M
J Pharm Sci; 2019 Oct; 108(10):3187-3193. PubMed ID: 31226425
[TBL] [Abstract][Full Text] [Related]
13. Levothyroxine sodium revisited: A wholistic structural elucidation approach of new impurities via HPLC-HRMS/MS, on-line H/D exchange, NMR spectroscopy and chemical synthesis.
Ruggenthaler M; Grass J; Schuh W; Huber CG; Reischl RJ
J Pharm Biomed Anal; 2017 Feb; 135():140-152. PubMed ID: 28024262
[TBL] [Abstract][Full Text] [Related]
14. Active drug substance impurity profiling part II. LC/MS/MS fingerprinting.
Nicolas EC; Scholz TH
J Pharm Biomed Anal; 1998 Jan; 16(5):825-36. PubMed ID: 9535195
[TBL] [Abstract][Full Text] [Related]
15. Direct analysis in real time--high resolution mass spectrometry as a valuable tool for the pharmaceutical drug development.
Srbek J; Klejdus B; Douša M; Břicháč J; Stasiak P; Reitmajer J; Nováková L
Talanta; 2014 Dec; 130():518-26. PubMed ID: 25159441
[TBL] [Abstract][Full Text] [Related]
16. Impurity profiling of liothyronine sodium by means of reversed phase HPLC, high resolution mass spectrometry, on-line H/D exchange and UV/Vis absorption.
Ruggenthaler M; Grass J; Schuh W; Huber CG; Reischl RJ
J Pharm Biomed Anal; 2017 Sep; 143():147-158. PubMed ID: 28599168
[TBL] [Abstract][Full Text] [Related]
17. Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC-ESI-QT/MS/MS.
Thomas S; Chandra Joshi S; Vir D; Agarwal A; Rao RD; Sridhar I; Xavier CM; Mathela CS
J Pharm Biomed Anal; 2012 Apr; 63():112-9. PubMed ID: 22361658
[TBL] [Abstract][Full Text] [Related]
18. Formation of reactive impurities in aqueous and neat polyethylene glycol 400 and effects of antioxidants and oxidation inducers.
Hemenway JN; Carvalho TC; Rao VM; Wu Y; Levons JK; Narang AS; Paruchuri SR; Stamato HJ; Varia SA
J Pharm Sci; 2012 Sep; 101(9):3305-18. PubMed ID: 22610374
[TBL] [Abstract][Full Text] [Related]
19. Applicability of mass spectrometry to detect coeluting impurities in high-performance liquid chromatography.
Antonovich RS; Keller PR
J Chromatogr A; 2002 Sep; 971(1-2):159-71. PubMed ID: 12350111
[TBL] [Abstract][Full Text] [Related]
20. Capillary electrophoresis-mass spectrometry in impurity profiling of pharmaceutical products.
Visky D; Jimidar I; Van Ael W; Vennekens T; Redlich D; De Smet M
Electrophoresis; 2005 Apr; 26(7-8):1541-9. PubMed ID: 15776482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
